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BACKGROUND: Atherosclerotic cardiovascular disease (heart attacks and 
strokes) is the major cause of death globally and is caused by the buildup 
of a plaque in the arterial wall. Genomic data showed that the B cell–
activating factor (BAFF) receptor pathway, which is specifically essential 
for the survival of conventional B lymphocytes (B-2 cells), is a key driver of 
coronary heart disease. Deletion or antibody-mediated blockade of BAFF 
receptor ablates B-2 cells and decreases experimental atherosclerosis. 
Anti-BAFF immunotherapy is approved for treatment of autoimmune 
systemic lupus erythematosus, and can therefore be expected to limit 
their associated cardiovascular risk. However, direct effects of anti-BAFF 
immunotherapy on atherosclerosis remain unknown.
METHODS: To investigate the effect of BAFF neutralization in 
atherosclerosis, the authors treated Apoe-/- and Ldlr-/- mice with a well-
characterized blocking anti-BAFF antibody. Moreover, to investigate the 
mechanism by which BAFF impacts atherosclerosis, the authors studied 
atherosclerosis-prone mice that lack the alternative receptor for BAFF: 
transmembrane activator and calcium modulator and cyclophilin ligand 
interactor.
RESULTS: The authors demonstrate here that anti-BAFF antibody 
treatment increased atherosclerosis in mice, despite efficient depletion 
of mature B-2 cells, suggesting a unique mechanism of action. Indeed, 
myeloid cell–specific deletion of transmembrane activator and calcium 
modulator and cyclophilin ligand interactor also results in increased 
atherosclerosis, while B cell–specific transmembrane activator and calcium 
modulator and cyclophilin ligand interactor deletion had no effect. 
Mechanistically, BAFF–transmembrane activator and calcium modulator 
and cyclophilin ligand interactor signaling represses macrophage IRF7-
dependent (but not NF-κB–dependent) Toll-like receptor 9 responses 
including proatherogenic CXCL10 production.
CONCLUSIONS: These data identify a novel B cell–independent anti-
inflammatory role for BAFF in atherosclerosis and may have important 
clinical implications.
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Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
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The Global Status Report on Noncommunicable Diseases 2014 issued by the World Health Organi-zation shows that heart attacks and strokes con-
tinue to be the major causes of mortality worldwide. 
A prominent pathology underlying these devastating 
clinical manifestations is atherosclerosis, a cholesterol-
driven chronic inflammatory disease of large- and medi-
um-size arteries that leads to the formation of plaques 
in the subendothelial space.1
B cell and humoral responses are decisively involved 
in the initiation and progression of atherosclerosis.2,3 
In addition, genomic and transcriptomic data of par-
ticipants of the Framingham study indicated prolifera-
tion and activation status of B cells to be key factors 
in determining cardiovascular disease (CVD) risk.4 The 
second most prominent candidate gene in this analysis 
was TNFRSF13C, which encodes 1 of the 3 known re-
ceptors for B cell–activating factor (BAFF), BAFF recep-
tor (BAFFR). In mice, disruption of BAFFR signaling re-
sults in ablation of, among others, conventional mature 
B-2 cells (follicular and marginal zone B cells), a very 
similar phenotype to anti-CD20 antibody (Ab)–treated 
mice.5–9 BAFFR-deficient, anti-BAFFR Ab–treated, and 
anti-CD20–treated mice display reduced atherosclero-
sis,5–9 suggesting that B-2 cells exhibit proatherogenic 
properties, and that targeting the BAFFR signaling 
pathway may be a therapeutic option for combating 
atherosclerotic CVD.
Alternative immunotherapies target the ligand of 
BAFFR, BAFF, which exists in multiple forms, including 
membrane-bound, soluble trimer, and 60-mer forms.10 
In 2011, the US Food and Drug Administration approved 
a blocking antibody against soluble BAFF as treatment 
in systemic lupus erythematosus patients. This anti-BAFF 
Ab, or a blocking anti-mouse BAFF Ab, leads to apopto-
sis of mature B cells in both humans11 and mice.12 How-
ever, whether the effect of anti-BAFF Ab treatment on 
atherosclerosis would recapitulate the results of previ-
ous B-2 cell depletion strategies is not clear.
Here, we report the unexpected finding that BAFF 
neutralization increases atherosclerotic plaque size 
and complexity despite efficient depletion of mature 
B-2 cells, and we provide evidence suggesting novel B 
cell–independent anti-inflammatory properties of BAFF. 
Consistent with that, we show that the expression of 
the alternative BAFF-binding receptor transmembrane 
activator and calcium modulator and cyclophilin ligand 
interactor (TACI) in myeloid cells limits atherosclerosis, 
demonstrating novel atheroprotective pathways.
METHODS
We are not able to make the materials used in this study avail-
able because of material transfer agreement restrictions.
Mice, Treatments, and Diets
Apoe-/- mice were purchased from Taconic (Denmark); Ldlr-
/-, Taci-/- and µMT mice were from The Jackson Laboratories 
(USA); and Rag2-/- mice were purchased from Charles River 
(Germany). All mice were on C57BL/6 background, and 
maintained either in the specific pathogen–free facility of 
the Medical University of Vienna (Austria) or the University 
of Cambridge (United Kingdom). Female Apoe-/- (9–10 
weeks old) and male Ldlr-/- (12–14 weeks old) mice were 
injected on day 0, 6, and 14 with 100 µg of either a neu-
tralizing hamster anti-mouse BAFF Ab (clone 10F4; provided 
by Human Genome Sciences and GlaxoSmithKline) or a 
control hamster polyclonal immunoglobulin (Ig) G (Jackson 
Immunoresearch). Preliminary atherosclerosis studies dem-
onstrated no effect of polyclonal IgG on lesion formation 
versus PBS. From day 14, mice were fed an atherogenic 
diet (0.2% cholesterol, 21% fat; E15721-347 bought from 
Ssniff, Germany) for 6 or 8 weeks, and continued to receive 
the antibody treatment once every 7 to 10 days. Taci-/- mice 
were crossed to Apoe-/- mice, and 6-week-old male Taci+/+, 
Taci+/-, and Taci-/- mice (on Apoe-/- background) were fed 
an atherogenic diet (21% fat, 0.15% cholesterol; Special 
Diet Services, United Kingdom) for 6 weeks. Because no 
significant differences between wild-type and heterozy-
gote mice were observed, data from Taci+/+ and Taci+/- mice 
were pooled. For bone marrow transplantation experiments, 
male Ldlr-/- mice (8–10 weeks old) were irradiated (10.5 Gy), 
then reconstituted with 1×107 donor bone marrow cells 
by IV injection. After a 4-week recovery period, mice were 
placed on an atherogenic diet for 8 weeks. To achieve B 
cell–specific—TACI-deficient chimeric mice, the 1×107 cells 
were made up of 80% µMT (B cell–deficient) with either 
20% Taci+/+ (control group) or 20% Taci-/- bone marrow. To 
create mice with myeloid (non–T cell and non–B cell)–spe-
cific deficiency in TACI, the donor bone marrow consisted 
of 20% C57BL6 wild-type bone marrow and either 80% 
Taci+/+Rag2-/- (control group) or 80% Taci-/-Rag2-/- bone mar-
row. All experimental studies were approved by the Animal 
Clinical Perspective
What Is New?
• Neutralization of B cell–activating factor leads 
to increased atherosclerotic plaque size and 
inflammation.
• Deletion of transmembrane activator and calcium 
modulator and cyclophilin ligand interactor or neu-
tralization of B cell–activating factor increases ath-
erosclerotic plaque size and inflammation.
What Are the Clinical Implications?
• Long-term neutralization of B cell–activating factor 
neutralization may promote atherosclerotic cardio-
vascular disease.
• Mutations in Tnfrsf13b (which encodes transmem-
brane activator and calcium modulating ligand 
interactor) that reduced transmembrane activator 
and calcium modulating ligand interactor signaling 
in humans, may confer increased cardiovascular risk.
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Ethics Committee of the Medical University of Vienna 
(BMWF-66.009/0368-WF/V/3b/2014), or have been regu-
lated under the Animals (Scientific Procedures) Act 1986 
Amendment Regulations 2012 following ethical review by 
the University of Cambridge Animal Welfare and Ethical 
Review Body (PPL PA4BDF775).
Flow Cytometry
Flow cytometry analysis of splenic and peritoneal B cell sub-
sets was performed as described previously,6,13 using directly 
conjugated antibodies on single cell suspensions of freshly 
isolated spleens and peritoneal cells. Peripheral blood was 
diluted with PBS + 2% dextran (Sigma) for at least 30 min-
utes at 37ºC to concentrate the erythrocytes at the bottom 
of the tube. The upper clear phase was collected, and cells 
were incubated with blocking anti-CD16/32 Ab (clone 93; 
eBiosciences). Peripheral monocytes and neutrophils were 
identified by staining with anti-CD11b (allophycocyanin) 
(clone M1/70; eBiosciences), anti-Ly6C fluorescein isothio-
cyanate (clone HK1.4; Biolegend), and anti-Ly6G phyco-
erythrin (clone 1A8; Biolegend). Resident peritoneal and 
splenic macrophages were stained with an anti-F4/80 Ab 
conjugated to APC (clone BM8; Biolegend). To quantify 
TACI expression, cells were stained with anti-TACI PE/APC 
and isotype control (anti-mouse IgD; clone 11-26c; eBiosci-
ences) where indicated. T regulatory cells were quantified 
using the Treg detection kit (Miltenyi). Data were acquired 
on a FACS Calibur or LSRII Fortessa (BD Pharmingen), and 
were analyzed using FlowJo software 7.6 (Treestar).
Serum Cholesterol Quantification
Blood was collected from the vena cava (in a MiniCollect 
Gold cap TUBE; Greiner Bio-One) or the heart at the time 
of sacrifice. Blood was centrifuged at 1000g for 30 min-
utes at room temperature. Serum total cholesterol was 
measured in an ISO 15189 accredited medical laboratory 
under standardized conditions on Beckman Coulter AU5400 
(Beckman Coulter) instruments, using the Beckman Coulter 
OSR6516 reagent, or by colorimetric assay kits bought from 
Biomerieux (cholesterol).
Quantification of Atherosclerotic Lesion 
Size
Atherosclerotic lesion size was evaluated by computer-
assisted image analysis using Adobe Photoshop Elements 6.0 
and ImageJ software, as previously described.14 For the stud-
ies with the anti-BAFF Ab, lesion size in the aortic root was 
quantified in hematoxylin and eosin–stained cross sections 
(n=9 per mouse) with 50-µm distance that were collected 
starting with the appearance of all 3 valve leaflets. For studies 
addressing the role of TACI, atherosclerosis was assessed in 
the aortic root on serial cryosections by Oil Red O staining, as 
previously described.6
Immunocytochemistry in Aortic Root 
Lesions
For quantification of collagen deposition, paraffin-embed-
ded lesions of aortic root were stained with Sirius Red F3B 
(CI 35782; Sigma-Aldrich). For macrophage content, sec-
tions of paraffin-embedded or cryo-sections of aortic root 
lesions were stained with an anti–MAC-3 (BD Pharmingen) 
or anti-MOMA2 Ab (Bio-Rad), respectively, as described 
previously.13,15 For CXCL10 quantification, sections were 
stained with a rabbit anti-CXCL10 Ab (using the commer-
cially available 10H11L3 clone that has been validated in 
paraffin-embedded spleen sections and in Western blot 
analysis of recombinant murine CXCL10 by the manufac-
turer; ThermoFisher). For caspase-3 quantification, we used 
an anticaspase-3 Ab (Cell Signaling) that specifically detects 
the cleaved form of caspase-3. Quantification was per-
formed with computer-assisted image analysis using Adobe 
Photoshop Elements 6.0 and ImageJ software.
Cytokine and Chemokine Quantification
Murine monocyte chemoattractant protein–1 (MCP-1) 
and keratinocyte chemoattractant (KC) were quantified 
in serum samples using the Luminex Technology Procarta 
Immunoassays (ThermoFisher). Human BAFF was measured in 
equal total protein lysates from human atherosclerotic plaque 
extracts from the Athero-Express clinical study.16,17
Bone Marrow–Derived and Peritoneal 
Macrophage Stimulation
Bone marrow cells were isolated from the femur and tibia 
of C57BL/6 wild-type mice and were cultivated for 7 days in 
RPMI1640 containing 10% fetal bovine serum and 1% peni-
cillin/streptomycin (all from Gibco), and supplemented with 
either 20% conditioned media (from L929 fibroblasts) or 40 
ng/mL of recombinant mouse M-CSF (macrophage colony-
stimulating factor; Biolegend). Cells were fed on day 3 with 
the media described above. Resident primary macrophages 
were isolated from the peritoneum of Rag1-/- mice by perito-
neal lavage in RPMI1640 containing 1% FBS and 1% penicil-
lin/ streptomycin. Peritoneal macrophages were plated in a 
96-well (flat-bottom) plate for at least 2 hours before stimu-
lation to allow adherence. To quantify the effect of BAFF in 
altering TLR9 responsiveness, peritoneal macrophages iso-
lated from Rag1-/- mice were stimulated with 0.8 µg/mL BAFF 
60-mer (which we had generated previously18) in RPMI1640 
containing 1% FBS and 1% penicillin/streptomycin overnight, 
after removing the BAFF-containing media, cells were also 
stimulated with 1 µmol/L CpG 1826 (Invitrogen) for 4 hours. 
At the end of the stimulation, cells were lysed in RLT buffer 
(Peqlab), which is suitable for RNA extraction. For M1 and 
M2 polarization, bone marrow–derived macrophages were 
stimulated with either 100 ng/mL interferon-γ (R&D Systems) 
(M1) or a mixture of 10 ng/mL IL-4 (interleukin-4) and 10 
ng/mL of IL-13 (interleukin-13) (both from R&D Systems) for 
24 hours. For phagocytosis assays, thymocytes were labeled 
with CellTracker Green CMFDA (5-chloromethylfluorescein 
diacetate) Dye (ThermoFisher), and then were incubated with 
1 µM of dexamethasone overnight. Then, apoptotic thymo-
cytes (>91% Annexin-V+) were added for 3 hours at 5:1 ratio 
to bone marrow–derived macrophages that had been stimu-
lated overnight with 0.8 µg/mL of BAFF 60-mer. Cells were 
then stained with anti-F4/80 (allophycocyanin; AbD Serotec) 
and analyzed by flow cytometry.
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Total RNA Extraction, cDNA Synthesis, 
and Real-Time Polymerase Chain Reaction 
Analysis
Total RNA was extracted with the peqGold total RNA kit (Peqlab), 
or by using TRIzol (Life Technologies) for snap-frozen cells or 
tissue. cDNA was synthesized using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). Quantitative 
Real-time SYBR Green–based polymerase chain reaction (Peqlab 
or Eurogentec) was performed on either a Bio-Rad CFX96 real-
time system or a Roche Lightcycler. 36B4 was used as reference 
gene. Data were analyzed using the ΔΔCT method.
Primer List
1. Cxcl10 forward: 5-GGATCCCTCTCGCAAGGA-3
2. Cxcl10 reverse: 5-ATCGTGGCAATGATCTCAACA-3
3. Cxcl10 forward: 5-GGTCTGAGTGGGACTCAAGG-3
4. Cxcl10 reverse: 5-GTGGCAATGATCTCAACACG-3
5. Ifit2 forward: 5-CACCTTCGGTATGGCAACTT-3
6. Ifit2 reverse: 5-TCAGCACCTGCTTCATCCAA-3
7. Cxcl1 forward: 5-GCTGGGATTCACCTCAAGAA-3
8. Cxcl1 reverse: 5-TCTCCGTTACTTGGGGACAC-3
9. Cxcl2 forward: 5-AGTGAACTGCGCTGTCAATG-3
10. Cxcl2 reverse: 5-TTCAGGGTCAAGGCAAACTT-3
11. Taci forward: 5-GCGCACCTGTACAGACTTC-3
12. Taci reverse: 5-GCCTCAATCCTGGACCATG-3
13. 36B4 forward: 5-AGGGCGACCTGGAAGTCC-3
14. 36B4 reverse: 5-CCCACAATGAAGCATTTTGGA-3
15. 36B4 forward: 5-GTCCTCGTTGGAGTGACATCG-3
16. 36B4 reverse: 5-TAGTTGGACTTCCAGGTCGC-3
Statistical Analyses
Statistical analyses were performed using Graph Pad Prism 
6 for Windows (Graph Pad Software). Experimental groups 
were compared using an unpaired or paired 2-tailed Student’s 
or Mann-Whitney test, or one-way ANOVA followed by 
Tukey’s test as appropriate. Data are presented as mean±SEM. 
A P value of <0.05 was considered significant.
RESULTS
Anti-BAFF Treatment Increases Size and 
Complexity of Atherosclerotic Plaques
To investigate the role of BAFF in atherosclerotic plaque 
development, we treated apolipoprotein E–deficient 
(Apoe-/-) mice fed an atherogenic diet for 6 weeks with 
a hamster antibody neutralizing mouse BAFF (10F4). 
Anti-BAFF–treated mice displayed similar body weight, 
plasma total cholesterol, and triglyceride levels com-
pared to control Ab (Ctrl)–treated mice (Table I in the 
online-only Data Supplement). As expected, anti-BAFF 
treatment resulted in robust reduction of B-2 cells (Fig-
ure 1A) and also in a slight reduction of splenic B-1 cells 
(Figure  1B). However, peritoneal B-1a and B-1b were 
proportionally increased or unaffected in anti-BAFF Ab–
treated Apoe-/- mice, while CD23+ B-2 cells were de-
creased (Figure  1C). Total plasma Igs were decreased 
in anti-BAFF compared to Ctrl Ab–treated Apoe-/- mice 
(Figure  1D). Furthermore, IgG antibodies—but not 
IgM—specific for the atherosclerosis-relevant oxidized 
low-density lipoprotein antigens malondialdehyde-
modified low-density lipoprotein and CuSO4-oxidized 
low-density lipoprotein were also decreased in anti-
BAFF–treated Apoe-/- mice (Figure  1E). Furthermore, 
B-1a–derived prototypic natural IgM such as T15/E06 
also remained unchanged (Figure  1E). Anti-BAFF Ab 
treatment did not alter splenic total CD4+ and T regula-
tory cell numbers (Figure IA and IB in the online-only 
Data Supplement). These effects of anti-BAFF treatment 
on the B cell system are very similar to those described 
before in anti-CD20–treated and Baffr-/- models of ath-
erosclerosis.2 Surprisingly, however, anti-BAFF Ab–treat-
ed mice developed larger atherosclerotic plaques (Fig-
ure 2A), which were further characterized by increased 
necrotic areas (Figure 2B) and decreased collagen con-
tent (Figure  2C), compared to Ctrl Ab–treated mice. 
Macrophage content (percentage of MAC-3+ area out 
of total lesion area) was not altered (α-BAFF: 28.1±3% 
versus Ctrl Ab: 33.9±2.5%). BAFF had no direct impact 
on macrophage efferocytosis in vitro (Figure II in the 
online-only Data Supplement). However, we found a 
trend toward increased cleaved caspase-3 content in 
plaques of anti-BAFF–treated Apoe-/- mice compared 
to Ctrl Ab–treated mice (α-BAFF: 2.1±0.7% versus Ctrl 
Ab: 0.9±0.4% caspase-3+ area out of total lesion area), 
suggesting a potential impairment of efferocytosis in 
vivo. Lesion size in the arch, thoracic, and abdominal 
aortas (quantified by the en face method) was not dif-
ferent between the 2 groups (α-BAFF: 3.3±0.5% versus 
Ctrl Ab: 4.6±0.5%). In addition, we found increased 
levels of proinflammatory KC cytokine and monocyte 
chemoattractant protein–1 chemokine in the serum of 
Apoe-/- mice that were treated with the anti-BAFF Ab 
(Figure 2D and 2E), which reflects increased systemic in-
flammation. We also tested the alternative atheroscle-
rosis-prone model, Ldlr-/- mice on a high-fat diet, and 
treated them with anti-BAFF Ab or Ctrl Ab. Similar to 
Apoe-/- mice, anti-BAFF treatment also resulted in ma-
ture B cell depletion and total plasma Ig reduction in 
Ldlr-/- mice (Figure IIIA through IIID in the online-only 
Data Supplement). Again, anti-BAFF Ab treatment did 
not change body weight, plasma total cholesterol, and 
triglyceride levels compared to Ctrl-treated Ldlr-/- mice 
(Table I in the online-only Data Supplement). Athero-
sclerotic plaque size in the aortic root (Figure 2F) and 
entire aorta (α-BAFF: 2.4±0.3% vs. Ctrl Ab: 2.2±0.4%) 
was similar between anti-BAFF– and Ctrl–treated Ldlr-
/- mice, however, anti-BAFF treatment led to increased 
macrophage lesional content (Figure 2G) and decreased 
collagen deposition (Figure 2H), indicative of more in-
flammatory advanced plaques. In line with this, and 
similar to Apoe-/- mice described above, Ldlr-/- mice that 
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received anti-BAFF Ab displayed strongly elevated levels 
of serum KC cytokine and monocyte chemoattractant 
protein–1 chemokine (Figure  2I and 2J). In addition, 
anti-BAFF–treated mice displayed increased circulating 
Ly6Chigh monocytes and neutrophils (Figure IIIE and IIIF 
in the online-only Data Supplement). Thus, anti-BAFF 
treatment promotes inflammation and atherogenesis in 
atherosclerosis-prone mice.
BAFF Antagonizes TLR9-IRF7 Responses 
in Macrophages
The sharply contrasting effects of anti-BAFF treatment, 
compared to anti-CD20 and anti-BAFFR therapies,5–9 
led us to explore B cell– and BAFFR-independent ef-
fects of BAFF. BAFF is expressed in human plaques, 
suggesting that BAFF expression may exhibit a local ef-
fect in plaques.19 We found that human atheromatous 
plaques contain more BAFF protein compared to fibro-
atheromatous plaques (Figure 3). These data support 
the local production of BAFF in plaques. Given the 
central role of monocytes/macrophages in immune cell 
regulation of atherosclerosis, we hypothesized that 
BAFF might affect macrophage responses directly and 
analyzed the expression of additional BAFF receptors. 
We found that bone marrow–derived macrophages, 
resident splenic macrophages, and peritoneal macro-
phages expressed the TACI receptor (Figure 4A), in line 
with a recent report.20 TACI expression was markedly 
augmented in M1 polarized macrophages (Figure 4B 
and 4C), which is the dominant macrophage subset 
in atherosclerotic lesions.21 Heterozygous mutations 
in the gene encoding TACI are associated with com-
mon variable immune deficiency.22 Common variable 
immune deficiency patients carrying such mutations 
display deregulated TLR9 signaling in B lymphocytes.23 
Figure 1. Anti-B cell–activating factor (BAFF) antibody treatment depletes mature B cells and reduces plasma total Ig titers in Apoe-/- mice.  
(A) Representative flow cytometry plots and bar graphs show absolute numbers of FO/T2 (blue), MZ (purple), CD21+CD23- B cells (red), T1 cells (green), and NF 
cells (gray), (B) absolute numbers of splenic B-1 cells defined as B220lowIgM+CD43+, (C) frequencies of peritoneal B-1a, B-1b, CD23+ B-2 cells, (D) total IgM, IgG1, 
IgG2b, IgG2c, IgG3, and IgA plasma antibody titers, and (E) plasma levels of T15id+ IgM, MDA-, and CuOx-LDL–specific IgG and IgM antibodies. Data are derived 
from Apoe-/- mice treated with a control (Ctrl) or an anti-BAFF neutralizing antibody (α-BAFF) while they were fed an atherogenic diet for 6 weeks (n=8 to 9 mice 
per group). All results show mean±SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 (Mann-Whitney U or unpaired Student’s t test). CuOx indicates CuSO4-
oxidized; Ig, immunoglobulin; LDL, low-density lipoprotein; MDA, malondialdehyde-modified; MZ, marginal zone; NF, newly formed; and RLU, relative light units.
D
ow
nloaded from
 http://ahajournals.org by on February 13, 2019
Tsiantoulas et al BAFF Neutralization Aggravates Atherosclerosis
November 13, 2018 Circulation. 2018;138:2263–2273. DOI: 10.1161/CIRCULATIONAHA.117.0327902268
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
These data suggest that BAFF-TACI signaling may be 
implicated in the regulation of TLR9 signaling. Thus, 
we investigated the impact of preincubation of peri-
toneal resident macrophages with TACI-activating 
recombinant BAFF 60-mer (which efficiently activates 
the TACI receptor in contrast to BAFF 3-mer, which 
specifically activates the BAFFR18) on TLR9 signaling 
responses. We found that BAFF specifically dampened 
TLR9-induced IRF7-dependent expression of interfer-
on-induced with tetratricopeptide repeats 2 (Ifit2) and 
the proatherogenic chemokine Cxcl1024 (Figure  4D), 
while it did not affect NF-κB–mediated Cxcl1 and Cxcl2 
expression (Figure  4E). In agreement with this, mice 
treated with the anti-BAFF Ab had increased CXCL10 
content in atherosclerotic plaques (Figure 4F). CXCL10 
has been shown to aggravate experimental athero-
sclerosis,24 and to be an independent prognostic fac-
tor for increased CVD risk in humans,25 providing a 
potential mechanism through which BAFF modulates 
atherosclerotic risk.
Myeloid Cell–Specific TACI Deletion 
Increases Atherosclerosis
Consistent with TACI-mediated atheroprotective effects 
of BAFF, we found that Apoe-/- Taci-/- mice fed an ath-
erogenic diet developed bigger atherosclerotic plaques, 
with more macrophages, compared to Apoe-/- Taci+/+ 
controls (Figure 5A and 5B). To identify the cell compart-
ment that is responsible for the atheroprotective effect 
of TACI, we studied atherosclerotic mice that lack TACI, 
specifically either in B cells (induced on transplantation 
of mixed Taci-/- and µMT bone marrow cells into lethal-
ly irradiated recipients; Figure IVA in online-only Data 
Supplement) or myeloid cells (induced on transplanta-
tion of mixed Taci-/- Rag2-/- and wild-type bone marrow 
Figure 2. Anti-B cell–activating factor (BAFF) antibody treatment aggravates atherosclerosis. 
(A) Representative photomicrographs of hematoxylin and eosin–stained aortic root lesions (50×) and dot plot of the average lesion size in the aortic root expressed 
as µm2 per section (400 µm), (B) dot plot of the average necrotic area in the aortic root, (C) representative photomicrographs of Sirius Red+ area in aortic root 
plaques, and serum (D) KC (keratinocyte chemoattractant) cytokine and (E) MCP-1 (monocyte chemoattractant protein-1) chemokine levels of Apoe-/- mice fed 
an atherogenic diet for 6 weeks and injected with a control (Ctrl) or an anti-BAFF neutralizing antibody (n=8 to 9 mice per group). (F) Representative photomicro-
graphs of hematoxylin and eosin–stained aortic root lesions (50×) and dot plot of the average lesion size in the aortic origin expressed as µm2 per section (400 µm), 
representative photomicrographs and dot plot of the average (G) MAC-3 and (H) Sirius Red+ area in aortic root plaques, and serum (I) KC cytokine and (J) MCP-1 
chemokine levels of Ldlr-/- mice fed an atherogenic diet for 8 weeks and injected with a Ctrl or an anti-BAFF neutralizing antibody (n=7 to 8 mice per group). Dots 
represent individual mice. All results show mean. *P<0.05, **P<0.01 (Mann-Whitney U or unpaired Student’s t test). Scale bar: 200 µm.
Figure 3. Increased B cell–activating factor (BAFF) protein content in 
atheromatous plaques.  
Dot plot of the average BAFF protein levels measured by ELISA in equal total 
protein extracts of human atherosclerotic plaques. Results show mean of 
n=14 samples per group. ***P<0.001 (unpaired t test).
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cells into lethally irradiated Ldlr-/- recipients; Figure IVB 
in online-only Data Supplement). In agreement with a 
B cell–independent role for BAFF in atherosclerosis, we 
found that atherogenic diet–fed Ldlr-/- mice with B cell–
specific deletion of TACI, which did not alter splenic 
B cell numbers (Figure VA in online-only Data Supple-
ment), or total cholesterol levels (Table I in online-only 
Data Supplement), did not impact atherosclerosis (Fig-
ure 5C). On the contrary, myeloid cell–specific deletion 
of TACI led to increased atherosclerosis (Figure 5D). In 
addition, and similar to the effect of global TACI defi-
ciency in Apoe-/- mice, myeloid cell–specific deletion of 
TACI in Ldlr-/- mice resulted in enhanced macrophage 
content (Figure 5E). Myeloid cell–specific TACI deletion 
did not change splenic B cells (Figure VB in online-only 
Data Supplement) or total plasma cholesterol levels 
(Table I in online-only Data Supplement). Furthermore, 
myeloid cell–specific TACI deletion resulted in increased 
Figure 4. B cell–activating factor (BAFF) antagonizes TLR9-IRF7 responses in macrophages.  
(A) Histograms of flow-cytometric analyses of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) expression in bone marrow–de-
rived macrophages (BMDMs) derived from wild-type and Taci-/- mice, and F4/80+ splenic and peritoneal macrophages isolated from Rag1-/- mice. (B) Mean fluorescence 
intensity of surface TACI expression measured by flow cytometry and (C) TACI gene expression quantified by real-time polymerase chain reaction (PCR) in BMDMs 
polarized to M1 or M2 phenotype. Data are representative of (A, BMDMs) (B) 2 independent experiments and (A; F4/80+ macrophages) of 3 mice. (D) Quantification 
of (D) Cxcl10 and Ifit2, and (E) Cxcl1 and Cxcl2 gene expression by real-time PCR in peritoneal resident macrophages (isolated from Rag1-/- mice) that were untreated 
or incubated with BAFF 60-mer (0.8 µg/mL) overnight, and then were stimulated with CpG (1µM) for 4 hours. (F) Dot plot shows the CXCL10+ area within plaques in 
the aortic root of Ldlr -/- mice treated with a control (Ctrl) or an anti-BAFF neutralizing antibody (α-BAFF) while they were fed an atherogenic diet for 8 weeks (described 
in Figure 2F and 2G and Figure III in the online-only Data Supplement; n=6–8 mice per group). (D and E) Data are representative of at least 2 to 3 independent experi-
ments. All results show mean±SEM. *P<0.05, **P<0.01 (unpaired Student’s t test, Mann-Whitney U test or 1-way ANOVA followed by Tukey’s test).
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expression of Cxcl10 and Ifit2 expression in the spleens 
of atherosclerotic mice in vivo (Figure 5F), mirroring the 
in vitro effects of BAFF-TACI signaling in regulating the 
TLR9-IRF7 pathway in macrophages.
DISCUSSION
The aim of the present study was to investigate the 
effect of BAFF neutralization in the development of 
atherosclerosis. Our data show that treatment with 
neutralizing anti-BAFF Ab detrimentally affects lesion 
development in 2 mouse models of atherosclerosis, 
without affecting lipid metabolism. Anti-BAFF treat-
ment induced characteristics of advanced atherosclero-
sis in both Apoe-/- and Ldlr-/- mice, such as decreased 
collagen content in plaques and increased levels of 
circulating proinflammatory KC cytokine and mono-
cyte chemoattractant protein–1 chemokine. However, 
we found it increased lesion size only in Apoe-/-, and 
not in Ldlr-/- mice. In our study, Apoe-/- mice were fed 
an atherogenic diet for 6 weeks and displayed big-
ger lesions with more inflammatory cells compared to 
Ldlr-/- mice. Along this line, we propose that the appar-
ent differences of BAFF blockade in the 2 models are 
linked to the different stage of atherosclerotic plaque 
development in Apoe-/- and Ldlr-/- mice under these set-
tings, rather than distinct mechanisms. Others recently 
reported that mice overexpressing both soluble and 
membrane-bound forms of BAFF (BAFF-transgenic)10 
exhibited decreased atherosclerosis in association with 
a profound (approximately 50%) reduction in plasma 
total cholesterol levels that are likely responsible for the 
effect observed in these mice.26 Moreover, although in-
formative, we believe that these BAFF-transgenic mice, 
which express at least 10 and up to 400 times higher 
levels of BAFF (ie, higher than what can be measured in 
any pathophysiological conditions in mice or humans), 
mostly reflect a pharmacological rather than a patho-
physiological setting. Mice with more physiologically 
relevant elevations of circulating BAFF, as is the case in 
B cell–deficient settings,27 do not show any alterations 
of plasma cholesterol levels. Furthermore, we are not 
aware of any report of reduced plasma cholesterol lev-
els in patients with high BAFF levels.
The atheroprotective effect of disrupted BAFF-BAF-
FR signaling has been attributed to depletion of con-
ventional proatherogenic B-2 cells.8,9 We show here 
that soluble BAFF also has the capacity to affect ath-
Figure 5. Myeloid-specific transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) signaling confers an atheroprotective 
effect. 
(A through C) Representative photomicrographs of Oil-Red O stained aortic root lesions and dot plot of the average lesion size in the aortic origin expressed as µm2 per 
section, and (B) representative photomicrographs and dot plot of the average MOMA-2+ area in aortic root plaques of the of (A) Apoe-/-Taci+/+ and Apoe-/-Taci-/- mice fed 
an atherogenic diet for 6 weeks (n=7 to 14 per group). (C and D) Representative photomicrographs of Oil-Red O stained aortic root lesions and dot plot of the average 
lesion size in the aortic origin expressed as µm2 per section of lethally irradiated Ldlr-/- mice transplanted with a mixture of bone marrow cells made up of (C) 80% µMT 
(B cell–deficient), with either 20% Taci+/+ (control group) or 20% Taci-/- bone marrow (n=10 per group) or (D) of 20% C57BL/6  wild-type bone marrow and either 80% 
Taci+/+Rag2-/- (control group) or 80% Taci-/-Rag2-/- bone marrow (n=13 to 15 per group), and were fed an atherogenic diet for 8 weeks. (E) Representative photomicro-
graphs and dot plot of the average MOMA-2+ area in aortic root plaques of the Ldlr-/- mice described in (D) (n=8 to 9 per group). (F) Quantification of Cxcl10 and Ifit2 
gene expression in the spleen of the Ldlr-/- mice described in (D), by real-time polymerase chain reaction (n=7 per group). Dots represent individual mice. All results show 
mean. *P<0.05 (Mann-Whitney U or unpaired Student’s t test).
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erosclerosis beyond changes in BAFFR signaling and B 
cell immunity, as atherosclerotic mice treated with the 
anti-BAFF neutralizing Ab display a similar reduction in 
mature B cells and circulating Ig levels, yet they develop 
increased atherosclerosis.
Notably, BAFFR-deficient mice also display robustly 
increased circulating BAFF levels.28 Thus, it is even pos-
sible that the increased soluble BAFF levels in BAFFR-
deficient5,6 or B cell–depleted8,9 mice might also con-
tribute to the atheroprotective effect in these settings. 
In addition to BAFFR, BAFF also binds to B cell matura-
tion antigen and TACI,10 which we found to be highly 
expressed in M1-like polarized macrophages. However, 
BAFF—in contrast to TACI—displays a particularly low 
affinity toward B cell maturation antigen, and thus we 
hypothesized that BAFF mediates its atheroprotective 
effect via the TACI receptor. Consistent with this, we 
show that global as well as myeloid-specific TACI dele-
tion increases atherosclerosis and macrophage lesional 
content, which suggests—in analogy to the anti-BAFF 
studies—that TACI impacts atherosclerosis via similar 
mechanisms in both models. The increased athero-
sclerosis in this study was associated with enhanced 
inflammatory markers, both locally and systemically. 
In addition, anti-BAFF treatment increased Ly6Chigh pe-
ripheral monocytes. Taken together, these data suggest 
that BAFF can affect monocyte/macrophage responses 
directly. Consistent with this, circulating CD14+CD16+ 
monocytes, which are a human equivalent to Ly6Chigh 
monocytes and have been shown to positively associate 
with human coronary atherosclerosis,29 are decreased in 
individuals with a genetic variant of TNFSF13B (which 
encodes BAFF and leads to increased soluble BAFF lev-
els).30 Peritoneal macrophages express BAFFR mRNA, 
though no protein was detected on the cell surface.20 
However, global BAFFR deficiency resulted in a similar 
atheroprotective effect to B cell–specific BAFFR dele-
tion,6 which suggests that lack of BAFFR signaling in 
macrophages is unlikely to be involved in the proath-
erogenic effect of anti-BAFF treatment. In addition to 
BAFF, TACI is also bound by the alternative ligand APRIL 
(A Proliferation Inducing Ligand).10 However, a recent 
study showed that APRIL overexpression in Apoe-/- mice 
does not affect atherosclerotic plaque size.31 Thus, it is 
unlikely that increased APRIL signaling in BAFFR-defi-
cient5,6 or B cell–depleted8,9 mice is responsible for the 
atheroprotective effects observed.
Anti-BAFF therapy is now considered to be a main 
line of treatment in a subset of systemic lupus erythe-
matosus patients, who exhibit a strong predisposition 
to premature atherosclerosis and heart attacks.32,33 The 
protective effect of BAFF inhibition in systemic lupus er-
ythematosus has been attributed to its B cell–depleting 
effect. However, rituximab treatment (anti-CD20 Ab), 
which provides a more efficient and rapid B cell deple-
tion, did not show any clinical benefit in systemic lupus 
erythematosus patients in 2 double-blind clinical tri-
als.34 Therefore, it is likely that long-term BAFF neutral-
ization in humans triggers additional effects (beyond B 
cell depletion and plasma auto-Ab reduction) that have 
important pathophysiological consequences. This is 
particularly interesting as we show that human athero-
matous plaques, which typically contain a higher num-
ber of inflammatory cells, have significantly increased 
levels of BAFF protein compared to fibroatheromatous 
plaques. Therefore, BAFF may affect macrophage re-
sponses locally, eg, by dampening proinflammatory re-
sponses such as CXCL10 expression, as we have shown, 
and/or preventing cell death in lesions. Indeed, it has 
been shown that stimulation of human monocytes with 
BAFF promotes cell survival.35
The role of TLR9 responses in atherosclerosis remains 
inconclusive. Our data suggest that preferential engage-
ment of the IRF7 or NF-κB pathway may determine the 
effect of TLR9 stimulation in macrophages on plaque 
formation.36,37 Koulis et al have shown that TLR9 dele-
tion promoted atherosclerosis, and that treatment with 
the TLR9 ligand CpG ODN 1668 reduced atherosclero-
sis.36 On the other hand, Krogmann et al demonstrated 
that treatment of atherosclerotic Apoe-/- mice with CpG 
ODN 1826 enhanced atherosclerosis.37 Our data sup-
port a proatherogenic role of the TLR9-IRF7 pathway. 
In line with this, it has been shown that treatment with 
CpG ODN 1585 increased CXCL10 production and 
enhanced atherosclerosis in Apoe-/- mice.38 We show 
that the BAFF-TACI signaling pathway preferentially 
represses IRF7-mediated responses in TLR9-stimulated 
macrophages, leading to decreased Cxcl10 expression. 
Notably, it has been reported that macrophages from 
TACI-deficient mice acquire an M2-like phenotype and 
display lower expression levels of TLR4 and TLR9.20 
These data suggest that TACI signaling might enhance 
the proinflammatory properties of macrophages (eg, in 
situations of hypercholesterolemia). Nevertheless, our 
data indicate that atherosclerotic mice lacking TACI 
signaling in myeloid cells express increased amounts 
of typical TLR9-induced genes, such as Ifit2 and Cxcl10 
transcripts, in their spleens and developed increased 
atherosclerosis. Furthermore, anti-BAFF treatment lead 
to increased CXCL10 content in plaques. CXCL10 has 
been shown to exhibit proatherogenic properties in ex-
perimental atherosclerosis,24 and to be an independent 
prognostic factor for increased CVD risk in humans.25 
Therefore, we propose that BAFF-TACI signaling re-
presses proatherogenic responses in macrophages un-
der hypercholesterolemic conditions.
While no accelerated CVD complications have been 
reported on anti-BAFF therapy so far, our findings 
introduce a new perspective with respect to the po-
tential cardiovascular hazard that may be associated 
with the blockade of BAFF in chronic cardiovascular 
inflammatory settings, in contrast to acute cardiovas-
D
ow
nloaded from
 http://ahajournals.org by on February 13, 2019
Tsiantoulas et al BAFF Neutralization Aggravates Atherosclerosis
November 13, 2018 Circulation. 2018;138:2263–2273. DOI: 10.1161/CIRCULATIONAHA.117.0327902272
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
cular inflammation.39 In conclusion, there is a need for 
more refined therapeutic approaches targeting the 
BAFF pathway.
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